STUDY OBJECTIVE: We describe our postmarketing experience with @entity1 receiving Crotalidae polyvalent immune @entity1334 (CroFab; FabAV) antivenom for treatment of rattlesnake @entity5900 . METHODS: The charts of 28 @entity1 admitted between @entity3490 and September 9, 2001, with rattlesnake @entity5900 and treated with FabAV were reviewed for demographic information, time until antivenom treatment, laboratory findings, evidence of @entity56 , length of hospital stay, and readmission to the hospital. RESULTS: All @entity1 had @entity4 , 20 @entity1 had elevated prothrombin times (>14 seconds), 12 @entity1 had low @entity2002 levels (<170 mg/dL), and 6 @entity1 had @entity882 (platelet count <120,000/mm(3)) on presentation. The total dose of FabAV ranged from 10 to 47 vials per @entity1 . @entity6805 was resistant to FabAV in some @entity1 . On follow-up, recurrence of @entity1003 was detected in 3 @entity1 , and recurrence of @entity882 was detected in 1 @entity1 . Two @entity1 demonstrated delayed-onset severe @entity882 . Recurrence or delayed-onset @entity137 might have been underestimated because of incomplete follow-up in some @entity1 . No acute @entity56 reactions occurred. Two @entity1 reported mild symptoms of possible serum sickness on follow-up. CONCLUSION: FabAV effectively controlled the effects of @entity5900 ; however, initial control of @entity1003 was difficult to achieve in some cases, and recurrence or delayed-onset hematotoxicity was common. When initially managing hematotoxicity, a trend toward normalization of laboratory values might be a more reasonable end point for FabAV treatment than attainment of normal reference values in nonbleeding @entity1 .

Initial postmarketing experience with crotalidae polyvalent immune @entity1334 for treatment of rattlesnake XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity2002 :: ('2244', 'Gene') :: ['fibrinogen'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity4 :: ('MESH:D004487', 'Disease') :: ['swelling'] @entity1003 :: ('MESH:D001778', 'Disease') :: ['coagulopathy'] @entity1334 :: ('2187', 'Gene') :: ['Fab'] @entity3490 :: ('55016', 'Gene') :: ['March 1'] @entity56 :: ('MESH:D004342', 'Disease') :: ['hypersensitivity reaction', 'hypersensitivity'] @entity6805 :: ('MESH:C531603', 'Disease') :: ['Hypofibrinogenemia'] @entity5900 :: ('MESH:D012909', 'Disease') :: ['envenomation']
@entity5900 :: (MESH:D012909,Disease) :: ['envenomation']
